8
Oct
2024

Medis ehf.

Exhibitor at CPHI Milan 2024 stand 10G17, Finished Dosage Formulations
About Us

Medis is a leader in pharmaceutical development and out licensing, offering a broad portfolio of quality pharmaceutical products and comprehensive registration dossiers and intellectual property since 1985. Medis is a powerful partner with a proven track record in securing regulatory approval prior to patent expiries, and has obtained marketing authorizations in over 140 countries to date. We out-license products from the pipeline of our parent company, Teva. Medis ehf is 100% owned by Teva Pharmaceutical Industries Ltd (NYSE, TASE: TEVA).

We o...

  • IS
  • 2015
    On CPHI since
  • 2
    Certificates
Company types
Manufacturer/Innovator
Contact info
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 10G17, Finished Dosage Formulations

Products Featured at CPHI Milan 2024

  • Out-licensing

    Product Out-licensing

    Medis is an established provider of dossiers and products in all areas of the world with launches and marketing authorizations in over 140 countries to date.